| 29th Oct 2020 7:00 am |
GNW |
Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2020 |
| 28th Oct 2020 11:01 am |
GNW |
Verona Pharma plc : Update on AIM Delisting |
| 23rd Oct 2020 5:30 pm |
RNS |
Verona Pharma |
| 22nd Oct 2020 7:00 am |
GNW |
Verona Pharma to Announce Interim Results for the Three and Nine Months Ended September 30, 2020 and Provide Corporate Update |
| 13th Oct 2020 7:00 am |
GNW |
Verona Pharma to Present Phase 2b COPD Symptom and Quality of Life Data with Ensifentrine at CHEST 2020 |
| 23rd Sep 2020 9:06 am |
GNW |
Verona Pharma Initiates Phase 3 Clinical Trials with Nebulized Ensifentrine for the Maintenance Treatment of COPD |
| 21st Sep 2020 7:00 am |
GNW |
Intended Delisting and Cancellation of Ordinary Shares from Trading on AIM |
| 17th Sep 2020 7:00 am |
GNW |
Verona Pharma to Ring the Nasdaq Closing Bell to celebrate $200 million financing |
| 16th Sep 2020 1:25 pm |
GNW |
Verona Pharma Announces Publication of Phase 2b COPD Symptom Data in the International Journal of Chronic Obstructive Pulmonary Disease |
| 8th Sep 2020 7:00 am |
GNW |
Verona Pharma Initiates Pilot Study with pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19 |
| 2nd Sep 2020 7:00 am |
GNW |
Verona Pharma to Present at H.C. Wainwright 22nd Annual Global Virtual Investment Conference |
| 26th Aug 2020 10:19 am |
GNW |
Verona Pharma plc: Grant of RADSUs and PDMR Dealings |
| 24th Aug 2020 7:00 am |
GNW |
Verona Pharma to Present Phase 2b data with Ensifentrine in COPD at the European Respiratory Society International Congress 2020 |
| 19th Aug 2020 7:00 am |
GNW |
Verona Pharma Initiates Multiple Dose Part of Phase 2 Clinical Trial with pMDI Formulation of Ensifentrine in COPD |
| 14th Aug 2020 11:05 am |
RNS |
Second Price Monitoring Extn |
| 14th Aug 2020 11:00 am |
RNS |
Price Monitoring Extension |
| 14th Aug 2020 7:00 am |
GNW |
Verona Pharma plc Operational Update and Financial Results for the Three and Six Months Ended June 30, 2020 |
| 7th Aug 2020 3:46 pm |
GNW |
Verona Pharma plc: TR-1: Standard form for notification of major holdings |
| 4th Aug 2020 6:13 pm |
GNW |
Verona Pharma plc: Issue of Equity, PDMR Dealings & Total Voting Rights |
| 3rd Aug 2020 7:00 am |
GNW |
Verona Pharma Announces August 2020 Virtual Investor Conference Participation |
| 30th Jul 2020 10:52 am |
GNW |
Verona Pharma plc: TR-1: Standard form for notification of major holdings |
| 30th Jul 2020 7:00 am |
GNW |
Verona Pharma to Announce Interim Results for the Three and Six Months Ended June 30, 2020 and Provide Corporate Update |
| 27th Jul 2020 7:01 am |
GNW |
Verona Pharma plc: TR-1: Standard form for notification of major holdings |
| 22nd Jul 2020 4:50 pm |
GNW |
Closing of Financing, Issued Share Capital and Total Voting Rights |
| 17th Jul 2020 5:47 pm |
GNW |
Verona Pharma plc: PDMR Dealings |
| 17th Jul 2020 7:00 am |
GNW |
Verona Pharma Raises $200 Million in Oversubscribed Private Placement and Subscription |
| 6th Jul 2020 4:04 pm |
GNW |
Verona Pharma plc: Issue of Equity and Total Voting Rights |
| 14th May 2020 7:00 am |
GNW |
Verona Pharma Announces FDA Response to End-of-Phase 2 Briefing Package for Ensifentrine in COPD and Outlines Phase 3 ENHANCE Clinical Program |
| 12th May 2020 1:11 pm |
GNW |
Director/PDMR Shareholding - Grant of Restricted Stock Units, Issue of Equity, Total Voting Rights & PDMR Dealings |
| 1st May 2020 5:12 pm |
GNW |
Verona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at the American Thoracic Society 2020 International Conference |
| 30th Apr 2020 7:00 am |
GNW |
Verona Pharma plc: Operational Update and Financial Results for the Three Months Ended March 31, 2020 |
| 23rd Apr 2020 7:00 am |
GNW |
Verona Pharma to Announce Financial Results for the Three Months Ended March 31, 2020 and Provide Corporate Update |
| 16th Apr 2020 12:12 pm |
GNW |
Verona Pharma plc: Results of AGM |
| 8th Apr 2020 7:00 am |
GNW |
Update on AGM Procedure |
| 31st Mar 2020 7:00 am |
GNW |
Verona Pharma Reports Positive Efficacy and Safety Data with Single Dose pMDI Formulation of Ensifentrine in COPD |
| 20th Mar 2020 11:28 am |
GNW |
Verona Pharma plc: Issue of Equity and Total Voting Rights |
| 17th Mar 2020 2:06 pm |
RNS |
Second Price Monitoring Extn |
| 17th Mar 2020 2:01 pm |
RNS |
Price Monitoring Extension |
| 16th Mar 2020 5:13 pm |
GNW |
2019 Annual Report and Accounts and Notice of AGM |
| 5th Mar 2020 4:01 pm |
GNW |
Grant of Restricted Stock Units and PDMR Dealings |
